HUBRECHT LAB has a total of 18 patent applications. Its first patent ever was published in 2005. It filed its patents most often in EPO (European Patent Office), Brazil and Canada. Its main competitors in its focus markets pharmaceuticals are ORAMED LTD, ZARODEX THERAPEUTICS LTD and PHARMACY AND THERAPEUTIC ADVIS.
# | Country | Total Patents | |
---|---|---|---|
#1 | EPO (European Patent Office) | 3 | |
#2 | Brazil | 2 | |
#3 | Canada | 2 | |
#4 | China | 2 | |
#5 | New Zealand | 2 | |
#6 | WIPO (World Intellectual Property Organization) | 2 | |
#7 | Israel | 1 | |
#8 | Mexico | 1 | |
#9 | Norway | 1 | |
#10 | United States | 1 | |
#11 | South Africa | 1 |
# | Industry | |
---|---|---|
#1 | Pharmaceuticals |
# | Technology | |
---|---|---|
#1 | Medical preparations | |
#2 | Therapeutic chemical compounds |
# | Name | Total Patents |
---|---|---|
#1 | Clevers Johannes Carolus | 14 |
#2 | Van Es Johannes Hendrikus | 12 |
#3 | Van Gijn Maria Elisabeth | 5 |
#4 | Carolus Clevers Johannes | 3 |
#5 | Es Johannes Hendrikus Van | 2 |
#6 | Hendrikus Es Johannes Van | 2 |
#7 | Elisabeth Gijn Maria Van | 1 |
#8 | Elisabeth Van Gijn Maria | 1 |
#9 | Gijn Maria Elisabeth Van | 1 |
#10 | Hendrikus Van Es Johannes | 1 |
Publication | Filing date | Title |
---|---|---|
EP1795198A1 | Treatment of Barret's esophagus | |
WO2006052128A1 | Treatment of an intestinal adenoma and/or adenocarcinoma by inhibition of notch pathway activation | |
ZA200704794B | Treatment of an instestinal adenoma and/or adenocarcinoma by inhibition of notch pathway activation |